Search Results for “mental health” – Page 46 – media

Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech

Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.
- Source: pharmalive
- 646
- May 11, 2018
Genentech Roche
Three Misconceptions and Four Suggestions to Pay Attention to in Foreign Trade

Foreign trade is a highly competitive field with numerous potholes and hidden issues. As a leader in the online pharmaceutical and medical device B2B industry, Ddu staff have in-depth knowledge of these matters. Today we’ll share our take on three misconceptions that are often overlooked and four important suggestions on how to approach your clients.
- Source: Ddu
- 6,742
- May 4, 2018
Ddu College misconceptions suggestions
In a medical first, drugs have reversed an inherited disorder in the womb

Doctors in Germany successfully treated twins in utero using a biotech drug, pointing to a new way to eliminate disease.
- Source: TechnologyReview
- 415
- April 28, 2018
digital health medtech Researches
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.
- Source: us.gsk
- 642
- April 27, 2018
Company Insights COPD FDA GSK
As FDA’s Pre-Cert plan takes shape, worries emerge about overreach

Yesterday morning, the FDA published its 17-page first draft of a working model for its pre-certification program for software as a medical device (SaMD). Though still preliminary (the agency is asking for comments by the end of May), the publication comes with some long-awaited details about how the program might work.
- Source: MobiHealthNews
- 615
- April 27, 2018
FDA medical device products Policies
Telemedicine robot enables physician consultations in multiple locations

Using the device, called a Beam, Miramont Family Medicine now sees more patients than ever – enabling physicians to be in more than one of its four locations at the same time.
- Source: HealthIT News
- 545
- April 17, 2018
Company Insights mHealth Telemedicine
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment

Although inflammatory arthritis can be treated systemically, drugs are often injected directly into affected areas, particularly when the disease affects just one or a few joints. Problem is, injectable drugs are usually cleared quickly from the joint, limiting their effectiveness. A new delivery system could improve the efficacy and durability of arthritis treatments, as well as cut down on nasty side effects caused by systemic therapy.
- Source: fiercebiotech
- 491
- April 8, 2018
arthritis Researches
Third Rock debuts immunometabolism startup Rheos with $60M launch round

Global pharmaceutical company Mylan N.V. (MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
- Source: pharmacompass
- 635
- March 30, 2018
financing immune Market Views
Male birth control pill shows early promise, but will it work?

An attempt to develop a safe and effective "male pill" is making headway, according to preliminary results of a small study. In a four-week trial of men under 50, an experimental hormone-based birth control pill was found to be "well-tolerated."
- Source: cbsnews
- 558
- March 27, 2018
contraception male pill Researches
Oxford Performance Materials targets Asia after 3D printed medical devices approved in Japan

Oxford Performance Materials, a company whose materials have been used in everything from medical implants to Boeing airplanes, has been given the green light to distribute its 3D printed medical devices in Japan, paving the way for major expansion within Asia.
- Source: 3Ders
- 537
- March 22, 2018
3D printing Japan medical device products New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.